Amyris Hasn't Even Begun To Be Overbought.
Long Only, Growth, Accountant
Seeking Alpha Analyst Since 2018
Accountant by trade. I like to do deep dives into financial statements and disclosures to get the full picture of the fundamentals. I look for value either via P/S or P/E in small cap growth stocks more specifically.
Summary
- Amyris (AMRS) is up 588% over the past three months.
- There is still value to be had when compared to peers.
- New opportunities for Biossance and Pipette, New consumer brands, vitamins, jet fuel, base oils and Monoclonal Antibodies will begin to make contributions in 2021 and thus Amyris is still very extremely underpriced.
Amyris Hasn't Even Begun To Be Overbought (AMRS)
Now an article - please see the above link.
Analyst's Disclosure: I am/we are long AMRS.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.